ACA minimum MLR rebate requirements
Regulatory Exposure
MLR floors cap margins in Commercial Insured, Medicare Advantage and Medicaid and leave the company exposed to higher-than-expected medical costs; repeated rebates trigger CMS enrollment bans/termination.
Relevance 95·Dependency 85·Confidence 95
Source evidence
“Minimum MLR rebate requirements limit the level of margin we can earn in Health Care Benefits’ Commercial Insured business.”
U.S. federal and state government programs (Medicare, Medicaid)
Revenue Exposure
Government funded businesses are highly sensitive to federal/state funding, policy, shutdown and debt ceiling risk; contracts cancellable on short notice.
Relevance 92·Dependency 88·Confidence 90
Source evidence
“Federal, state and local governments have the right to cancel or not to renew their contracts with us on short notice without cause or if funds are not available.”
U.S. federal government programs (Medicare/Medicaid)
Revenue Exposure
Federal government-funded programs account for a significant portion of revenues; funding disruption would hurt revenues and operating results.
Relevance 92·Dependency 85·Confidence 94
Source evidence
“Programs funded in whole or in part by the U.S. federal government account for a significant portion of our revenues”
Prescription drugs
Supplier Dependency
Pharmacy & Consumer Wellness segment, mail order/specialty pharmacy and PBM revenues depend on relationships with prescription drug manufacturers and suppliers; termination or modification could materially adversely affect results.
Relevance 90·Dependency 85·Confidence 95
Source evidence
“we are dependent on our relationships with prescription drug manufacturers and suppliers.”
Inflation Reduction Act (IRA)
Regulatory Exposure
IRA Part D redesign shifts claim liability to plans effective 2025, affecting the Medicare Part D product economics and offering flexibility.
Relevance 90·Dependency 80·Confidence 93
Source evidence
“a complete redesign of the Medicare Part D standard benefit effective in 2025, which may reduce the Company’s flexibility to design competitive offerings.”
Prescription drugs
Raw Material Dependency
Drug availability, pricing and safety profiles affect products purchased and sold across the pharmacy and PBM businesses.
Relevance 88·Dependency 80·Confidence 92
Source evidence
“We face risks relating to the market availability, pricing, suppliers and safety profiles of prescription drugs and other products that we purchase and sell.”
Working Families Tax Cut Act / One Big Beautiful Bill Act (2025)
Regulatory Exposure
2025 Medicaid eligibility/financing changes reduce enrollment and state funding, pressuring Medicaid benefits and payment rates.
Relevance 88·Dependency 75·Confidence 92
Source evidence
“makes changes to Medicaid eligibility rules and financing which will lead to reduced eligibility for Medicaid beneficiaries, particularly expansion populations, and reduced state funding”
HHS/state premium rate review
Regulatory Exposure
Rate reviews and state limits restrict ability to price for medical cost increases, ACA fees and taxes, compressing Insured Health Care Benefits margins.
Relevance 85·Dependency 75·Confidence 90
Source evidence
“Rate reviews can magnify the adverse impact on our operating margins, MBRs and operating results of increases in health care and other benefit costs, increased utilization of covered services, and ACA assessments, fees and taxes, by restricting our ability to reflect these increases and/or these assessments, fees and taxes in our pricing.”
Minimum MLR rebate requirements
Regulatory Exposure
MLR rebate rules cap insurance margin while the company remains exposed to higher-than-expected medical costs.
Relevance 85·Dependency 75·Confidence 92
Source evidence
“Minimum MLR rebate requirements limit the level of margin we can earn in our Insured Health Care Benefits products while leaving us exposed to higher than expected medical costs.”
Pharmacy reimbursement pressure
Cost Driver
Continued pharmacy reimbursement pressure offset revenue growth and pressured segment margins (operating income fell as % of revenues from 4.6% to 3.5%).
Relevance 85·Dependency 70·Confidence 94
Source evidence
“partially offset by continued pharmacy reimbursement pressure and the impact of recent generic drug introductions”
False Claims Act / CMS audits
Legal Exposure
Failure to report/correct errors found in CMS audits could bring fines, civil monetary penalties, or exclusion affecting participation in Medicare Advantage, Part D and other government programs.
Relevance 85·Dependency 70·Confidence 90
Source evidence
“we could be subject to fines, civil monetary penalties or other sanctions, including fines and penalties under the False Claims Act, which could have a material adverse effect on our ability to participate in Medicare Advantage, Medicare Part D or other government programs”
Generic prescription drugs
Cost Driver
Generic margin compression from reduced reimbursement and manufacturer consolidation raising acquisition costs directly affects pharmacy operating results.
Relevance 82·Dependency 70·Confidence 90
Source evidence
“Consolidation within the generic drug manufacturing industry and other external factors may enhance the ability of manufacturers to sustain or increase pricing of generic drugs and diminish our ability to negotiate reduced generic drug acquisition costs.”
Branded GLP-1 drugs
Demand Driver
Pharmacy same store sales growth of 18.0% in 2025 was primarily driven by pharmacy drug mix including branded GLP-1 drugs.
Relevance 80·Dependency 55·Confidence 93
Source evidence
“The increase was primarily driven by pharmacy drug mix, including branded GLP-1 drugs, and the 8.0% increase in pharmacy same store prescription volume”
PBM-affiliated pharmacy licensure legislation
Regulatory Exposure
Vertical integration strategy could be impaired by legislation prohibiting state licensure of PBM-affiliated pharmacies.
Relevance 78·Dependency 65·Confidence 90
Source evidence
“legislation prohibiting state licensure of pharmacies affiliated with a PBM”
Prescription utilization
Demand Driver
Prescriptions filled increased 5.4% in 2025 primarily driven by increased utilization, supporting pharmacy revenue growth.
Relevance 75·Dependency 60·Confidence 90
Source evidence
“Prescriptions filled increased 5.4% on a 30-day equivalent basis in 2025 compared to 2024 primarily driven by increased utilization”
Litigation, class actions and qui tam actions
Legal Exposure
Routine litigation including class and qui tam actions seeks substantial damages not necessarily covered by insurance.
Relevance 75·Dependency 55·Confidence 92
Source evidence
“We routinely are subject to litigation and other adverse legal proceedings, including class actions and qui tam actions.”
U.S. import tariffs
Regulatory Exposure
Significant changes in tax or trade policies, tariffs or trade relations could significantly increase costs and restrict access to suppliers of imported drugs and merchandise.
Relevance 75·Dependency 55·Confidence 92
Source evidence
“significant changes in tax or trade policies, tariffs or trade relations between the U.S. and other countries, such as the imposition of unilateral tariffs on imported products, could result in significant increases in our costs, restrict our access to suppliers”
$929 million of litigation charges in 2025 related to the Omnicare long-term care business; Omnicare was deconsolidated in Q3 2025.
Relevance 70·Dependency 40·Confidence 93
Source evidence
“$929 million in litigation charges recorded in 2025 related to the Omnicare long-term care business”
Rite Aid prescription files
Demand Driver
Acquisition of Rite Aid prescription files added incremental prescription volume, driving 2025 pharmacy revenue and adjusted operating income growth.
Relevance 70·Dependency 35·Confidence 92
Source evidence
“primarily driven by increased prescription volume, including incremental volume resulting from the Company’s Rite Aid prescription file acquisitions”
Health plan members / medical membership
Demand Driver
Joint ventures and risk-sharing arrangements may expand into new geographies, target new customer groups and increase membership; failure would reduce medical membership growth and competitiveness.
Relevance 65·Dependency 55·Confidence 85
Source evidence
“These arrangements also may allow us to expand into new geographies, target new customer groups, increase membership and reduce medical costs”
Provider and supplier consolidation
Competitive Exposure
Continuing consolidation among providers and suppliers may increase the company's costs and increase competition.
Relevance 65·Dependency 50·Confidence 88
Source evidence
“Continuing consolidation and integration among providers and other suppliers may increase our costs and increase competition.”
Generic drug introductions
Cost Driver
Recent generic drug introductions partially offset pharmacy revenue growth in 2025.
Relevance 65·Dependency 50·Confidence 90
Source evidence
“partially offset by continued pharmacy reimbursement pressure and the impact of recent generic drug introductions”
Natural disasters and extreme weather events
Cost Driver
Natural disasters and extreme weather events, which may increase in frequency or intensity due to climate change, drive health care benefit costs.
Relevance 60·Dependency 45·Confidence 85
Source evidence
“natural disasters and extreme weather events (which may increase in frequency or intensity as a result of climate change)”
Investment income largely driven by U.S. interest rate levels; U.S. credit market and monetary policy volatility can reduce portfolio value, net investment income and debt issuance capacity.
Relevance 55·Dependency 60·Confidence 90
Source evidence
“the income we earn from our investment portfolio is largely driven by the level of interest rates in the U.S.”
Target Corporation
Revenue Exposure
Store counts include retail drugstores and pharmacies located within Target stores.
Relevance 55·Dependency 30·Confidence 85
Source evidence
“Includes retail drugstores and pharmacies within retail chains, primarily in Target Corporation (“Target”) stores.”